1. Italy Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Philogen SpA

Philogen SpA

MMIL:PHIL
21.25
EUR
-0.15
(-0.70%)
938.55MMarket Cap
Mar 25Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.13
0.06
0.58
0.57
1.84
7.8
- -
Basic EPS, GAAP
-0.37
-0.4
-0.13
-0.15
1.12
5.7
- -
Free Cash Flow per Basic Share
-0.47
-0.65
-0.23
-0.27
0.95
6.56
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.37
2.59
2.42
2.25
3.44
9.28
9.28
Tangible Book Value per Share
1.35
2.57
2.39
2.22
3.41
9.25
9.25
Basic Weighted Avg Shares
36
40
41
40
40
40
40
Sales/Revenue/Turnover
5
2
24
23
74
314
- -
Operating Margin (%)
-254
-662.22
3.46
-35.98
51.82
82.11
- -
Depreciation Expense
1
2
3
4
4
4
- -
Net Income, GAAP
-13
-16
-5
-6
45
230
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
11.7
- -
Profit Margin (%)
-278.05
-630.01
-22.67
-26.64
61.21
73.07
- -
Working Capital
55
97
88
77
116
347
347
LT Debt
11
11
11
11
10
10
10
Total Equity
56
105
98
91
139
374
374
Return on Invested Capital (%)
- -
- -
- -
- -
- -
79.97
- -
Return on Capital (%)
- -
- -
- -
- -
- -
85.99
- -
Return on Common Equity (%)
- -
-19.56
-5.3
-6.54
39.51
89.63
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
10
10
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
786
865
939

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
132
119
398
Cash, Cash Equivalents & STI
114
100
379
Accounts Receivable, Net
1
1
1
Inventories
3
4
3
Total Current Liabilities
17
21
51
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
59.43%
169.63%
Free Cash Flow
- -
26.84%
587.82%
Net Income, GAAP
- -
-92.18%
407.1%
Sales/Revenue/Turnover
- -
268.9%
324.79%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
23
2024
- -
- -
74
2025
- -
- -
314

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.15
2024
- -
- -
1.12
2025
- -
- -
5.7

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dario Neri
Full Time Employees
214
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Via Bellaria, 35 Siena SI Italy 53018
IPO Date
Mar 3, 2021
Website
philogen.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Philogen S.p.A. (PHIL.MI) is a biotechnology company focused on the discovery, development, and commercialization of biopharmaceutical products for the treatment of cancer and other serious diseases. The company offers a pipeline of monoclonal antibody-based therapeutics and targeted radiopharmaceuticals, including tumor-selective antibody-drug conjugates such as Nidlegy (targeting ED-B fibronectin for melanoma), Daromun (for soft tissue sarcoma), and PhilMab products; radiolabeled antibodies like Philotensine and 89Zr-DFO-7C9 for diagnostic imaging; and innovative services in antibody engineering and clinical development. Operations span research, manufacturing, and clinical trials primarily in Europe, with headquarters in Siena, Italy, where it was founded in 1996, and additional facilities in Switzerland and the UK. Philogen targets oncology markets, serving patients and healthcare providers through partnerships with academic institutions and pharmaceutical firms. In recent developments within the last two years, the company advanced Phase III trials for Nidlegy in advanced melanoma, expanded manufacturing capabilities for commercial-scale production, and strengthened strategic alliances for radiopharmaceutical distribution in key European markets.